{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:50:34Z","timestamp":1787017834419,"version":"build-2736575974"},"reference-count":59,"publisher":"Wiley","license":[{"start":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T00:00:00Z","timestamp":1640649600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Basic Research Program of China","doi-asserted-by":"publisher","award":["2017YFC1308902"],"award-info":[{"award-number":["2017YFC1308902"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Basic Research Program of China","doi-asserted-by":"publisher","award":["31671298"],"award-info":[{"award-number":["31671298"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2017YFC1308902"],"award-info":[{"award-number":["2017YFC1308902"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31671298"],"award-info":[{"award-number":["31671298"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Immunology Research"],"published-print":{"date-parts":[[2021,12,28]]},"abstract":"<jats:p>\n                    Background and Aims. Biomarkers for systemic inflammation have been introduced into clinical practice for risk-rating in cancer patients\u2019 treatment. This study is aimed at confirming the prognostic role of the neutrophil-to-lymphocyte ratio (NLR) as an effective biomarker for patients with metastatic gastric cancer (MGC) receiving anti-PD-1 agents. Method. Patients with MGC who received anti-PD-1 treatment at the Chinese PLA General Hospital between January 2016 and November 2020 were reviewed. The study analyzed the association of NLR and overall survival (OS) or progression-free survival (PFS) and antitumor response rate with PD-1 inhibitors. Results. 137 patients were included in the final analysis. The area under the curve value of NLR for 6-month OS was 0.71. The best cut-off value for NLR was 3.23.\n                    <jats:inline-formula>\n                      <a:math xmlns:a=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M1\">\n                        <a:mtext>NLR<\/a:mtext>\n                        <a:mo>&lt;<\/a:mo>\n                        <a:mn>3.23<\/a:mn>\n                      <\/a:math>\n                    <\/jats:inline-formula>\n                    was associated with longer OS (\n                    <jats:inline-formula>\n                      <c:math xmlns:c=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M2\">\n                        <c:mtext>HR<\/c:mtext>\n                        <c:mo>=<\/c:mo>\n                        <c:mn>0.38<\/c:mn>\n                      <\/c:math>\n                    <\/jats:inline-formula>\n                    , 95% CI, 0.26-0.57,\n                    <jats:inline-formula>\n                      <e:math xmlns:e=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M3\">\n                        <e:mi>p<\/e:mi>\n                        <e:mo>&lt;<\/e:mo>\n                        <e:mn>0.001<\/e:mn>\n                      <\/e:math>\n                    <\/jats:inline-formula>\n                    ) and PFS (\n                    <jats:inline-formula>\n                      <g:math xmlns:g=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M4\">\n                        <g:mtext>HR<\/g:mtext>\n                        <g:mo>=<\/g:mo>\n                        <g:mn>0.42<\/g:mn>\n                      <\/g:math>\n                    <\/jats:inline-formula>\n                    , 95% CI, 0.29-0.62,\n                    <jats:inline-formula>\n                      <i:math xmlns:i=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M5\">\n                        <i:mi>p<\/i:mi>\n                        <i:mo>&lt;<\/i:mo>\n                        <i:mn>0.001<\/i:mn>\n                      <\/i:math>\n                    <\/jats:inline-formula>\n                    ) in patients with MGC. No significant difference was observed in the objective response rate (ORR) (35.8% vs. 28.6%,\n                    <jats:inline-formula>\n                      <k:math xmlns:k=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M6\">\n                        <k:mi>p<\/k:mi>\n                        <k:mo>=<\/k:mo>\n                        <k:mn>0.377<\/k:mn>\n                      <\/k:math>\n                    <\/jats:inline-formula>\n                    ) and disease control rate (DCR) (86.4% vs. 78.6%,\n                    <jats:inline-formula>\n                      <m:math xmlns:m=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M7\">\n                        <m:mi>p<\/m:mi>\n                        <m:mo>=<\/m:mo>\n                        <m:mn>0.229<\/m:mn>\n                      <\/m:math>\n                    <\/jats:inline-formula>\n                    ) in the\n                    <jats:inline-formula>\n                      <o:math xmlns:o=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M8\">\n                        <o:mtext>NLR<\/o:mtext>\n                        <o:mo>&lt;<\/o:mo>\n                        <o:mn>3.23<\/o:mn>\n                      <\/o:math>\n                    <\/jats:inline-formula>\n                    group and in the\n                    <jats:inline-formula>\n                      <q:math xmlns:q=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M9\">\n                        <q:mtext>NLR<\/q:mtext>\n                        <q:mo>\u2265<\/q:mo>\n                        <q:mn>3.23<\/q:mn>\n                      <\/q:math>\n                    <\/jats:inline-formula>\n                    group, respectively. Univariate analysis and multivariate analysis found that NLR was an independent prognosis biomarker for PFS and OS. Conclusions. Pretreatment elevated NLR was significantly associated with inferior PFS and OS in patients with MGC who received anti-PD-1 inhibitors. Clinicians need to consider patients with elevated NLR for decisions on immunotherapy strategy.\n                  <\/jats:p>","DOI":"10.1155\/2021\/2549295","type":"journal-article","created":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T18:21:33Z","timestamp":1640715693000},"page":"1-9","source":"Crossref","is-referenced-by-count":40,"title":["Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric Cancer"],"prefix":"10.1155","volume":"2021","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9622-1198","authenticated-orcid":true,"given":"Miaomiao","family":"Gou","sequence":"first","affiliation":[{"name":"Medical Oncology Department, The First Medical Center, Chinese PLA General Hospital, Fuxing Road 28, Haidian District, Beijing, 100853, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongtong","family":"Qu","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, The First Medical Center, Chinese PLA General Hospital, Fuxing Road 28, Haidian District, Beijing, 100853, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhikuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, The First Medical Center, Chinese PLA General Hospital, Fuxing Road 28, Haidian District, Beijing, 100853, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7966-0359","authenticated-orcid":true,"given":"Huan","family":"Yan","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, The First Medical Center, Chinese PLA General Hospital, Fuxing Road 28, Haidian District, Beijing, 100853, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhai","family":"Si","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, The First Medical Center, Chinese PLA General Hospital, Fuxing Road 28, Haidian District, Beijing, 100853, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7375-7296","authenticated-orcid":true,"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, The Second Medical Center, Chinese PLA General Hospital, Fuxing Road 28, Haidian District, Beijing, 100853, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7339-3840","authenticated-orcid":true,"given":"Guanghai","family":"Dai","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, The First Medical Center, Chinese PLA General Hospital, Fuxing Road 28, Haidian District, Beijing, 100853, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21338"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_175228"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu472"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2016.05.009"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.9929"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1111\/jebm.12362"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.4_suppl.2"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01307"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy540"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0013"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31827-5"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31257-1"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.18_suppl.LBA4007"},{"key":"14","doi-asserted-by":"crossref","first-page":"S1142","DOI":"10.1016\/j.annonc.2020.08.2297","article-title":"LBA7_PR - nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric\/gastroesophageal junction (G\/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study","volume":"31","author":"N. Boku","year":"2020","journal-title":"Annals of Oncology"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0101-z"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz197"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-019-1941-0"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1111\/dote.12296"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/8345286"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2008.05.046"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1007\/s00595-017-1587-6"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004381"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0383-1"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.570113"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5903-y"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-04023-w"},{"key":"27","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-016-2330-1"},{"key":"28","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-020-00716-y"},{"key":"29","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/7862469"},{"key":"30","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13381"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000010144"},{"key":"32","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341X.2000.00337.x"},{"key":"33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2017.03.029"},{"key":"34","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S153290"},{"key":"35","article-title":"Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer\/gastroesophageal junction cancer\/esophageal adenocarcinoma: first results of the CheckMate 649 study","volume":"31, article S1191","author":"M. Moehler","year":"2020","journal-title":"Annals of Oncology"},{"key":"36","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-018-0144-x"},{"key":"37","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-010-0554-3"},{"key":"38","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2018\/e360"},{"key":"39","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000001189"},{"key":"40","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-2032-0"},{"key":"41","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-2583"},{"issue":"4","key":"42","first-page":"256","article-title":"Tumor-infiltrating lymphocytes and prognosis of hepatocellular carcinoma","volume":"22","author":"A. Kawata","year":"1992","journal-title":"Japanese Journal of Clinical Oncology"},{"key":"43","doi-asserted-by":"publisher","DOI":"10.1097\/01.mpa.0000188305.90290.50"},{"key":"44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2018.02.003"},{"key":"45","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-015-0409-0"},{"key":"46","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S138039"},{"key":"47","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.12655"},{"key":"48","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7819-11-112"},{"key":"49","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-013-0330-2"},{"key":"50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.11.012"},{"key":"51","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0386"},{"key":"52","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3603"},{"key":"53","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30445-9"},{"key":"54","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.2298"},{"key":"55","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5441"},{"key":"56","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02107"},{"key":"57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596"},{"key":"58","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2015.12.006"},{"key":"59","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0864-3"}],"container-title":["Journal of Immunology Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/jir\/2021\/2549295.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/jir\/2021\/2549295.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/jir\/2021\/2549295.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T18:21:39Z","timestamp":1640715699000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/jir\/2021\/2549295\/"}},"subtitle":[],"editor":[{"given":"Qiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,12,28]]},"references-count":59,"alternative-id":["2549295","2549295"],"URL":"https:\/\/doi.org\/10.1155\/2021\/2549295","relation":{},"ISSN":["2314-7156","2314-8861"],"issn-type":[{"value":"2314-7156","type":"electronic"},{"value":"2314-8861","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12,28]]}}}